Physician Assistant Program
Objective: To further analyze if GLP-1 agonists are more effective in weight loss in obese patients with type 2 diabetes or without type 2 diabetes over the course of 1 year. Obesity has an increasing prevalence in those with and without type 2 diabetes so the need to find a treatment that can potentially treat both diseases can lead to less comorbidities and better outcomes. Methods: Online databases were used to find academic sources that compared the use of GLP-1 agonists for weight loss in those with and without type 2 diabetes. Ten sources, including meta analyses, retrospective cohorts, narrative reviews, and systematic reviews published within the last 5 years were included in this research paper. Results: GLP-1 agonists, such as Liraglutide and Semaglutide, were found to be statistically more effective for weight loss in adult patients who do not have type 2 diabetes over those with type 2 diabetes. Patients with type 2 diabetes were still found to have more weight loss with a GLP-1 agonist than with a placebo, but those without type 2 diabetes had significantly higher weight loss.
Comerford, Alyssa, "GLP-1 Agonists Effects on Weight Loss in Those With and Without Diabetes" (2023). Summer Interdisciplinary Research Symposium. 158.